Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences (NASDAQ:XBIO) has extended its Research Funding Agreement with the University of Virginia (UVA) through 2025 to advance its DNase-based oncology platform. The program targets neutrophil extracellular traps (NETs) in the tumor microenvironment, which promote cancer spread and immunosuppression. Preclinical studies have shown that reducing NETs burden with Xenetic's recombinant human DNase I improves the efficacy of immunotherapy, adoptive cell therapy, and chemotherapy.
The company maintains an option to exclusively license new intellectual property from the research program. UVA will continue investigating DNase I combinations with immunotherapies in primary and metastatic colorectal cancer models. Xenetic is progressing toward its first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
Xenetic Biosciences (NASDAQ:XBIO) ha esteso il suo Accordo di Finanziamento per la Ricerca con l'Università della Virginia (UVA) fino al 2025 per sviluppare la sua piattaforma oncologica basata su DNasi. Il programma si concentra sulle trappole extracellulari dei neutrofili (NETs) nell'ambiente tumorale, che favoriscono la diffusione del cancro e l'immunosoppressione. Studi preclinici hanno mostrato che ridurre il carico di NETs con la DNasi I umana ricombinante di Xenetic migliora l'efficacia della immunoterapia, della terapia cellulare adottiva e della chemioterapia.
L'azienda mantiene un'opzione per licenziare esclusivamente nuove proprietà intellettuali dal programma di ricerca. UVA continuerà a indagare le combinazioni di DNasi I con immunoterapie in modelli di cancro colorettale primario e metastatico. Xenetic sta progredendo verso il suo primo studio clinico per valutare la DNasi combinata con inibitori dei checkpoint immunitari o chemioterapia.
Xenetic Biosciences (NASDAQ:XBIO) ha ampliado su Acuerdo de Financiamiento de Investigación con la Universidad de Virginia (UVA) hasta 2025 para avanzar en su plataforma oncológica basada en DNasa. El programa se centra en las trampas extracelulares de neutrófilos (NETs) en el microambiente tumoral, que favorecen la propagación del cáncer y la inmunosupresión. Los estudios preclínicos han demostrado que reducir la carga de NETs con la DNasa I humana recombinante de Xenetic mejora la eficacia de la inmunoterapia, la terapia celular adoptiva y la quimioterapia.
La empresa mantiene la opción de licenciar exclusivamente nueva propiedad intelectual del programa de investigación. UVA continuará investigando combinaciones de DNasa I con inmunoterapias en modelos de cáncer colorrectal primario y metastásico. Xenetic avanza hacia su primer estudio en humanos para evaluar la DNasa combinada con inhibidores de puntos de control inmunitarios o quimioterapia.
Xenetic Biosciences (NASDAQ:XBIO)는 버지니아 대학교(UVA)와의 연구 자금 지원 계약을 2025년까지 연장하여 DNase 기반 암 치료 플랫폼을 발전시키고 있습니다. 이 프로그램은 종양 미세 환경에서 암의 확산과 면역 억제를 촉진하는 호중구 세포외 트랩(NETs)을 표적으로 하고 있습니다. 전임상 연구에 따르면 Xenetic의 재조합 인간 DNase I로 NETs의 부하를 줄이면 면역 요법, 세포 이식 요법 및 화학 요법의 효능이 향상됩니다.
회사는 연구 프로그램에서 새로운 지적 재산권을 독점적으로 라이센스할 옵션을 유지하고 있습니다. UVA는 일차 및 전이성 대장암 모델에서 DNase I과 면역 요법의 조합을 계속 조사할 것입니다. Xenetic은 면역 검사점 억제제 또는 화학 요법과 결합된 DNase를 평가하기 위한 최초의 인간 연구로 나아가고 있습니다.
Xenetic Biosciences (NASDAQ:XBIO) a prolongé son Accord de Financement de Recherche avec l'Université de Virginie (UVA) jusqu'en 2025 pour faire avancer sa plateforme oncologique basée sur DNase. Le programme cible les pièges extracellulaires des neutrophiles (NETs) dans le microenvironnement tumoral, qui favorisent la propagation du cancer et l'immunosuppression. Des études précliniques ont montré que la réduction de la charge de NETs avec la DNase I humaine recombinante de Xenetic améliore l'efficacité de l'immunothérapie, de la thérapie cellulaire adoptive et de la chimiothérapie.
L'entreprise maintient la possibilité de licencier exclusivement de nouvelles propriétés intellectuelles issues du programme de recherche. UVA continuera à étudier les combinaisons de DNase I avec des immunothérapies dans des modèles de cancer colorectal primaire et métastatique. Xenetic progresse vers sa première étude sur l'homme pour évaluer la DNase combinée avec des inhibiteurs de points de contrôle immunitaires ou une chimiothérapie.
Xenetic Biosciences (NASDAQ:XBIO) hat seine Forschungsförderungsvereinbarung mit der University of Virginia (UVA) bis 2025 verlängert, um seine auf DNase basierende Onkologie-Plattform voranzutreiben. Das Programm richtet sich gegen neutrophile extrazelluläre Fallen (NETs) in der Tumormikroumgebung, die die Verbreitung von Krebs und Immunosuppression fördern. Präklinische Studien haben gezeigt, dass die Reduzierung der NETs-Belastung mit Xenetics rekombinanter menschlicher DNase I die Wirksamkeit von Immuntherapie, adoptiver Zelltherapie und Chemotherapie verbessert.
Das Unternehmen behält sich die Option vor, neue geistige Eigentumsrechte aus dem Forschungsprogramm exklusiv zu lizenzieren. UVA wird weiterhin die Kombinationen von DNase I mit Immuntherapien in Modellen von primärem und metastasiertem kolorektalem Krebs untersuchen. Xenetic schreitet auf seine erste klinische Studie zu, um DNase in Kombination mit Immun-Checkpoint-Inhibitoren oder Chemotherapie zu bewerten.
- Successful extension of research agreement with prestigious UVA institution
- Preclinical data shows improved efficacy when combining DNase with existing cancer treatments
- Option to acquire exclusive licensing rights for new intellectual property
- Still in preclinical stage with no human trials initiated yet
- Additional research and development costs through 2025
Insights
The extension of the research agreement with UVA represents continued momentum in developing Xenetic's DNase-based oncology platform. The technology's mechanism targeting NETs in the tumor microenvironment shows promise, with preclinical data demonstrating enhanced efficacy of existing cancer treatments when combined with DNase. The focus on colorectal cancer models and the partnership with Dr. Tsung, an expert in NETs research, strengthens the scientific foundation.
However, investors should note that XBIO remains in early research stages with no immediate revenue potential. With a micro-cap status (<money>$6.2M</money>) and the extended timeline through 2025, significant clinical and regulatory hurdles lie ahead before any potential commercialization. The intellectual property option provides some strategic value, but substantial funding will likely be needed to advance through clinical trials.
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications
FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025.
Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the tumor microenvironment (TME) and blood, thereby promoting cancer spread, local and systemic immunosuppression, as well as cancer-associated thrombosis. Reduction of NETs burden via application of Xenetic's proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models.
"Allan Tsung, MD, and the team at UVA continue to be valued partners and we are pleased with the progress under the Agreement in evaluating the potential addition of DNase to available treatment options in areas of significant unmet need. The preclinical and translational data that UVA has accumulated under the initial Scope of Work to the Agreement further strengthens the scientific rationale for investigating combinations of DNase I with immunotherapies and chemotherapies. In the next phase of this partnership, UVA will continue to investigate combinations of DNase I with immunotherapies in models of primary and metastatic colorectal cancer. As a surgical oncologist and scientist, Dr. Tsung is internationally recognized for leading substantial research on the role of NETs in tumor growth, metastasis, and resistance to existing cancer therapies and we look forward to leveraging that expertise as we advance our technology toward the clinic," commented Reid P. Bissonnette, Ph.D., Executive Consultant for Translational Research and Development of Xenetic.
Under the terms of the Agreement, in addition to advancing Xenetic's existing intellectual property, Xenetic has an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Allan Tsung, MD, a member of the Company's Scientific Advisory Board and Chair of the Department of Surgery at the UVA School of Medicine, will continue to oversee the research conducted under the Agreement. Xenetic is working toward its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase I platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma, colorectal cancer and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "making", and other words of similar meaning, including, but not limited to: all statements regarding the collaboration agreement with UVA, including regarding the next phase of the partnership with UVA where UVA will continue to investigate combinations of DNase I with immunotherapies in models of primary and metastatic colorectal cancer and our plans to continue to leverage the knowledge and expertise of the team at UVA to potentially expand and broaden the utility of our proprietary platform technology; and expectations regarding our DNase-based oncology platform, including statements regarding: advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications; focusing on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications; advancing the development of the Company's program on the combination of systemic DNase and CAR T-cell therapies; the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression; and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma, colorectal cancer and locally advanced or metastatic solid tumors. All forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) failure to achieve the expected outcomes and realize the anticipated benefits from our collaboration agreements, including the agreement with UVA; (2) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the agreement with UVA; (3) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (4) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (5) failure to realize the anticipated potential of the DNase or PolyXen technologies; (6) the ability of the Company to obtain funding and implement its business strategy; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com
FAQ
What are the key findings of XBIO's DNase-based oncology platform in preclinical studies?
When will XBIO begin human trials for its DNase-based cancer treatment?
What is the duration of XBIO's extended research agreement with UVA?
What cancer types is XBIO targeting with its DNase therapy research?
What intellectual property rights does XBIO have under the UVA agreement?
